v3.25.1
Consolidated Statements of Changes in Shareholders' (Deficit) Equity - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Other reserves
Accumulated other comprehensive income / (loss)
Accumulated losses
Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021   71,246,000          
Beginning balance at Dec. 31, 2021 $ (31,729) $ 279,932 $ 350,200 $ (728) $ (18,065) $ (574,801) $ (68,267)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock – based compensation expense 7,292   7,292        
Foreign currency translation adjustment $ 1,973       1,973    
Exercise of stock-based awards (in shares) 48,172 1,070,000          
Exercise of stock-based awards $ 367 $ 7,621 (7,254)        
Net loss for the year (68,521)         (68,521)  
Treasury Stock (10,000)           (10,000)
Accretion of Series A non-convertible preferred shares (11,884)   (11,884)        
Accrual of cumulative dividends of Series A non-convertible preferred shares (15,375)   (15,375)        
Accretion of redeemable non-controlling interest (473)   (473)        
Accrual of dividends of Series B convertible preferred shares (2,000)   (2,000)        
Redemption of non-controlling interest 3,200   3,200        
Ending balance (in shares) at Dec. 31, 2022   72,316,000          
Ending balance at Dec. 31, 2022 (127,150) $ 287,553 323,706 (728) (16,092) (643,322) (78,267)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock – based compensation expense 3,454   3,454        
Foreign currency translation adjustment $ 4,434       4,434    
Exercise of stock-based awards (in shares) 3,827 592,000          
Exercise of stock-based awards $ 27 $ 4,673 (4,646)        
Net loss for the year 24,490         24,490  
Accretion of Series A non-convertible preferred shares (13,324)   (13,324)        
Accrual of cumulative dividends of Series A non-convertible preferred shares (15,750)   (15,750)        
Accrual of dividends of Series B convertible preferred shares (2,000)   (2,000)        
Ending balance (in shares) at Dec. 31, 2023   72,908,000          
Ending balance at Dec. 31, 2023 (125,819) $ 292,226 291,440 (728) (11,658) (618,832) (78,267)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock – based compensation expense 9,901   9,901        
Foreign currency translation adjustment $ (22,492)       (22,492)    
Exercise of stock-based awards (in shares) 14,414 525,000          
Exercise of stock-based awards $ 107 $ 10,044 (9,937)        
Net loss for the year 27,905         27,905  
Accretion of Series A non-convertible preferred shares (14,982)   (14,982)        
Accrual of cumulative dividends of Series A non-convertible preferred shares (15,229)   (15,229)        
Exercise of convertible preferred stock 46,700   (20,779)       67,479
Accrual of dividends of Series B convertible preferred shares (499)   (499)        
Issuance of stock in cashless exercise of warrants (in shares)   10,993,000          
Ending balance (in shares) at Dec. 31, 2024   84,426,000          
Ending balance at Dec. 31, 2024 $ (94,408) $ 302,270 $ 239,915 $ (728) $ (34,150) $ (590,927) $ (10,788)